home > ict

International Clinical Trials


International Clinical Trials (ICT) is a specialist journal designed to provide global coverage of key topics pertinent to the clinical trials sector.

Published quarterly, and edited by Dr Graham Hughes, the journal offers a platform of communication and information-sharing for executive and strategic decision-makers, seeking out new trends and marketing opportunities, as well as putting a spotlight on the latest innovations coming to market. ICT is specifically designed to be of interest to those actively seeking to source services for improved efficiency in what is an increasingly competitive market.

For further information please contact:

Nick Matthews   

Rupert Gilbey


View the digital version of ICT

Featured in this issue
Drug Safety

Active Ingredients

Doing business in new markets brings greater exposure to safety and regulatory risks. Chitra Lele at Sciformix examines how this is prompting a shift to a more proactive pharmacovigilance model with data analysis, stakeholder input and benefit-risk balance at its core.
Site Performance

Going Metric

A shared, consistent set of standards and metrics to assess the performance of clinical research sites is moving closer due to an ongoing multi-stakeholder initiative. Greg Koski and Mary Tobin at ACRES, and Eve Shalley at Essex Management report.
Regulatory Update

Europe in Harmony?

The incoming Clinical Trials Regulation will simplify and speed up trial applications and approvals across Europe. But, as Peter Kennerley and Clara Ezed from Emas Pharma make clear, potential hurdles lie in wait, such as get-out clauses and differences in medical practice and language.

Edited by
Dr Graham Hughes
Consultant in

Published quarterly in
February, May,
August and November
Banner of Biorepositories IIR.ICT on Samedan
Banner of PAREXEL.ICT on Samedan
Banner of UBC.ICT on Samedan
Industry Events

Cancer Vaccines

15-16 September 2014, Holiday Inn Regents Park, London UK

The global therapeutic cancer vaccines market is expected to grow to a value of $7.8 billion by 2019. As companies look to develop new drugs to enter this rapidly growing industry, Cancer Vaccines 2014 will mark the path forward in terms of cancer vaccine research, clinical development and regulation.
More info >>

News and Press Releases

Comprehend Raises $21 Million in Series B Funding

REDWOOD CITY, CALIF. – August 18, 2014 – Comprehend today announced it has secured $21 million in Series B financing to accelerate clinical development through its cloud-based business intelligence solutions, enabling life science companies to bring new treatments and devices to market faster and more affordably. The round was led by Lightspeed Venture Partners with support from existing investor Sequoia Capital. Lightspeed partner Peter Nieh joined the company’s board of directors.
More info >>

air transport logo


White Papers

Clinical Trials in Russia Orange Paper: 2nd Quarter 2014

Synergy Research Group

The Ministry of Health of Russian Federation approved 194 new clinical trials of all types including local and bioequivalence studies during the 2nd Quarter of 2014 (3% less than at the same period of the last year). The main contribution to the total number of studies was made by multinational multi-center clinical trials (MMCT) and the number of these studies stayed the same as in Q2 2013 – 81 studies. The number of bioequivalence studies (BE) decreased from 76 studies in Q2 2013 to 59 in Q2 2014, a 22% decrease from last year’s figure. The number of local clinical trials (LCT) increased from 42 in Q2 2013 to 54 clinical trials in Q2 2014.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement